Treatment of Inflammatory Bowel Disease with Biologics

333

Infectious complications, 187–193, 202
and biologic therapy, 186
adalimumab, 189
anti-integrin antibodies, 190
certolizumab, 189
in children, 193
clinical awareness, 202
concomitant narcotics, 187
corticosteroids, 187
epidemiology, 187, 188
golimumab safety, 190
immunosuppressants, 187
with infliximab, 187, 189
interleukin 12/23 monoclonal
antibody, 192
management, 202
medication usage, 192
natalizumab, 191
in older patients, 193
preventive screening, 202
surveillance guidelines, 202
ustekinumab, 192
vedolizumab, 191
host resistance, 187
immunosuppressant medications, 186
inflammatory activity, 186
Inflammatory bowel diseases (IBD), 141
CD (see Crohn’s disease (CD))
UC (see Ulcerative colitis (UC))
Inflammatory cascade antagonists
filgotinib, 310
mongerson, 310
risankizumab, 309
tofacitinib, 309
ustekinumab, 308
Infliximab, 16, 19, 20, 34–36, 38, 133, 134,
137, 138
CD, 33
clinical efficacy, 33–36
cost effective, 36
fistula healing, 36
infectious complications, 133, 134
maintenance therapy, 36
mucosal healing, 36
and immunomodulators, 137
intra-abdominal abscesses, 130
pediatric CD, 163–167
perioperative treatment, 136
postoperative complications, 136
pouch-specific complications, 136
steroid-sparing agent, 130
surgical morbidity, 135
UC

children, 167–169

hepatotoxicity, 247

induction and maintenance clinical

trials, 16

infectious complications, 137, 138

infusion reactions, 20

long-term maintenance therapy, 19

mucosal improvement, 19

safety, 20

tolerence, 19

Interchangeability, 273–275

Invasive pneumococcal disease, 186

L

Leucocyte trafficking, 284, 285

antagonists

ertrolizumab, 305, 306

ozanimod, 307

PF-00547659, 306, 307

vedolizumab, 304, 305

Liver function tests (LFT), 323

Lupus-like syndrome (LLS)

clinical presentation, 243

diagnosis, 245

immunologic criteria, 244

management, 246

pathophysiology, 245

risk factors, 244

M

Medical therapy, 129, 138

Melanoma, 218

Mongerson, 304, 310, 311

N

Natalizumab, 286

Non-Hodgkin’s lymphoma, 219

Non-melanoma skin cancer (NMSC), 216, 217

O

Older adults, anti-TNFα, 24, 25

Ozanimod, 304, 307

P

Patient Protection and Affordable Care Act,

262

Pediatric Crohn’s disease

corticosteroid usage, 165

Index